Improving vaccine efficacy against malignant glioma

OncoImmunology

Volumn 5, Issue 8, 2016, Pages

  Ladomersky, Erik ^a   Genet, Matthew ^a   Zhai, Lijie ^a   Gritsina, Galina ^a   Lauing, Kristen L ^a   Lulla, Rishi R ^a,b,c   Fangusaro, Jason ^a,b,c   Lenzen, Alicia ^a,c   Kumthekar, Priya ^a,b   Raizer, Jeffrey J ^a,b   Binder, David C ^d   James, C David ^a,b   Wainwright, Derek A ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cancer immunity; cancer vaccines; Dendritic cell vaccine; glioma; HSPPC 96; Immunosuppression; pediatric glioma; Rindopepimut

Indexed keywords

CANCER VACCINE; EPHRIN RECEPTOR A2; HISTONE H3; HISTONE H3 K27M; IMMUNOGLOBULIN; INTERLEUKIN 13 RECEPTOR ALPHA2; PROPHAGE SERIES G 100; RINDOPEPIMUT; SURVIVIN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VITESPEN;

CANCER CHEMOTHERAPY; CELL INFILTRATION; CELL THERAPY; DENDRITIC CELL; GLIOBLASTOMA; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; MEDIAN SURVIVAL TIME; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; VACCINATION;

EID: 84982806196     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1196311     Document Type: Review

References (122)

1. Q.T.Ostrom, H.Gittleman, P.Liao, C.Rouse, Y.Chen, J.Dowling, Y.Wolinsky, C.Kruchko, J.Barnholtz-Sloan. CBTRUS statistical report:primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 2014; 16 Suppl 4:iv1-63; PMID:25304271; http://dx.doi.org/10.1093/neuonc/nou223
2. J.Ferlay, E.Steliarova-Foucher, J.Lortet-Tieulent, S.Rosso, J.W.Coebergh, H.Comber, D.Forman, F.Bray. Cancer incidence and mortality patterns in Europe:estimates for 40 countries in 2012. Eur J Cancer 2013; 49(6):1374-403; PMID:23485231; http://dx.doi.org/10.1016/j.ejca.2012.12.027
3. I.Soerjomataram, J.Lortet-Tieulent, D.M.Parkin, J.Ferlay, C.Mathers, D.Forman, F.Bray. Global burden of cancer in 2008:a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 2012; 380(9856):1840-50; PMID:23079588; http://dx.doi.org/10.1016/S0140-6736(12)60919-2
4. 2015 CBTRUS Fact Sheet. 2015 [cited 2015December7]; Available from:http://www.cbtrus.org/factsheet/factsheet.html
5. Q.T.Ostrom, H.Gittleman, L.Stetson, S.M.Virk, J.S.Barnholtz-Sloan. Epidemiology of gliomas. Cancer Treat Res 2015; 163:1-14; PMID:25468222; http://dx.doi.org/10.1007/978-3-319-12048-5_1
6. P.Y.Wen, S.Kesari. Malignant gliomas in adults. N Engl J Med 2008; 359(5):492-507; PMID:18669428; http://dx.doi.org/10.1056/NEJMra0708126
7. R.Stupp, M.E.Hegi, W.P.Mason, M.J.van den Bent, M.J.Taphoorn, R.C.Janzer, S.K.Ludwin, A.Allgeier, B.Fisher, K.Belanger et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study:5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10(5):459-66; PMID:19269895; http://dx.doi.org/10.1016/S1470-2045(09)70025-7
8. R.Stupp, W.P.Mason, M.J.van den Bent, M.Weller, B.Fisher, M.J.Taphoorn, K.Belanger, A.A.Brandes, C.Marosi, U.Bogdahn et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352(10):987-96; PMID:15758009; http://dx.doi.org/10.1056/NEJMoa043330
9. D.R.Johnson, B.P.O'Neill. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 2012; 107(2):359-64; PMID:22045118; http://dx.doi.org/10.1007/s11060-011-0749-4
10. R.T.Eagan, E.T.Creagan, H.F.Bisel, D.D.Layton, Jr, R.V.Groover, R.C.Herman, Jr. Phase II studies of dianhydrogalactitol-based combination chemotherapy for recurrent brain tumors. Oncology 1981; 38(1):4-6; PMID:7443176; http://dx.doi.org/10.1159/000225511
11. R.T.Eagan, R.P.Dinapoli, R.C.Hermann, Jr, R.V.Groover, D.D.Layton, Jr, M.Scott. Combination carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation. Cancer Treat Rep 1982; 66(8):1647-9; PMID:7105055
12. R.T.Eagan, M.Scott. Evaluation of prognostic factors in chemotherapy of recurrent brain tumors. J Clin Oncol 1983; 1(1):38-44; PMID:6321671
13. M.Haid, J.D.Khandekar, M.Christ, C.M.Johnson, S.J.Miller, G.Y.Locker, J.M.Merrill, H.Reisel, A.Hatfield, V.Lanzotti et al. Aziridinylbenzoquinone in recurrent, progressive glioma of the central nervous system. A Phase II study by the Illinois Cancer Council. Cancer 1985; 56(6):1311-5; PMID:4027870; http://dx.doi.org/10.1002/1097-0142(19850915)56:6%3c1311::AID-CNCR2820560615%3e3.0.CO;2-V
14. R.M.Prins, H.Soto, V.Konkankit, S.K.Odesa, A.Eskin, W.H.Yong, S.F.Nelson, L.M.Liau. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011; 17(6):1603-15; PMID:21135147; http://dx.doi.org/10.1158/1078-0432.CCR-10-2563
15. R.R.Lulla, A.M.Saratsis, R.Hashizume. Mutations in chromatin machinery and pediatric high-grade glioma. Sci Adv 2016; 2(3):e1501354; PMID:27034984; http://dx.doi.org/10.1126/sciadv.1501354
16. J.C.Rodrigues, G.C.Gonzalez, L.Zhang, G.Ibrahim, J.J.Kelly, M.P.Gustafson, Y.Lin, A.B.Dietz, P.A.Forsyth, V.W.Yong et al. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol 2010; 12(4):351-65; PMID:20308313; http://dx.doi.org/10.1093/neuonc/nop023
17. B.Raychaudhuri, P.Rayman, J.Ireland, J.Ko, B.Rini, E.C.Borden, J.Garcia, M.A.Vogelbaum, J.Finke. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol 2011; 13(6):591-9; PMID:21636707; http://dx.doi.org/10.1093/neuonc/nor042
18. A.El Andaloussi, Y.Han, M.S.Lesniak. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg 2006; 105(3):430-7; PMID:16961139; http://dx.doi.org/10.3171/jns.2006.105.3.430
19. A.El Andaloussi, M.S.Lesniak. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol 2006; 8(3):234-43; PMID:16723631; http://dx.doi.org/10.1215/15228517-2006-006
20. D.A.Wainwright, P.Nigam, B.Thaci, M.Dey, M.S.Lesniak. Recent developments on immunotherapy for brain cancer. Expert Opin Emerg Drugs 2012; 17(2):181-202; PMID:22533851; http://dx.doi.org/10.1517/14728214.2012.679929
21. C.Uyttenhove, L.Pilotte, I.Théate, V.Stroobant, D.Colau, N.Parmentier, T.Boon, B.J.Van den Eynde. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9(10):1269-74; PMID:14502282; http://dx.doi.org/10.1038/nm934
22. X.Zhang, A.Wu, Y.Fan, Y.Wang. Increased transforming growth factor-beta2 in epidermal growth factor receptor variant III-positive glioblastoma. J Clin Neurosci 2011; 18(6):821-6; PMID:21511480; http://dx.doi.org/10.1016/j.jocn.2010.09.024
23. C.Huettner, W.Paulus, W.Roggendorf. Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol 1995; 146(2):317-22; PMID:7856743
24. T.Nitta, M.Hishii, K.Sato, K.Okumura. Selective expression of interleukin-10 gene within glioblastoma multiforme. Brain Res 1994; 649(1–2):122-8; PMID:7953624; http://dx.doi.org/10.1016/0006-8993(94)91055-3
25. O.Bloch, C.A.Crane, R.Kaur, M.Safaee, M.J.Rutkowski, A.T.Parsa. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res 2013; 19(12):3165-75; PMID:23613317; http://dx.doi.org/10.1158/1078-0432.CCR-12-3314
26. A.T.Parsa, J.S.Waldron, A.Panner, C.A.Crane, I.F.Parney, J.J.Barry, K.E.Cachola, J.C.Murray, T.Tihan, M.C.Jensen et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007; 13(1):84-8; PMID:17159987; http://dx.doi.org/10.1038/nm1517
27. C.B.Thompson, J.P.Allison. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997; 7(4):445-50; PMID:9354465; http://dx.doi.org/10.1016/S1074-7613(00)80366-0
28. P.E.Fecci, H.Ochiai, D.A.Mitchell, P.M.Grossi, A.E.Sweeney, G.E.Archer, T.Cummings, J.P.Allison, D.D.Bigner, J.H.Sampson. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 2007; 13(7):2158-67; PMID:17404100; http://dx.doi.org/10.1158/1078-0432.CCR-06-2070
29. D.A.Wainwright, A.L.Chang, M.Dey, I.V.Balyasnikova, C.K.Kim, A.Tobias, Y.Cheng, J.W.Kim, J.Qiao, L.Zhang et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4 and PD-L1 in mice with brain tumors. Clin Cancer Res 2014; 20(20):5290-301; PMID:24691018; http://dx.doi.org/10.1158/1078-0432.CCR-14-0514
30. A.T.Ogden, D.Horgan, A.Waziri, D.Anderson, J.Louca, G.M.McKhann, M.B.Sisti, A.T.Parsa, J.N.Bruce. Defective receptor expression and dendritic cell differentiation of monocytes in glioblastomas. Neurosurg 2006; 59(4):902-9; discussion 909-10; PMID:17038955; http://dx.doi.org/10.1227/01.NEU.0000233907.03070.7B
31. D.C.Binder, A.A.Davis, D.A.Wainwright. Immunotherapy for cancer in the central nervous system:current and future directions. Onco Immunol 2015; 5(2):e1082027; PMID:27057463; http://dx.doi.org/10.1080/2162402X.2015.1082027
32. S.S.Bullain, A.Sahin, O.Szentirmai, C.Sanchez, N.Lin, E.Baratta, P.Waterman, R.Weissleder, R.C.Mulligan, B.S.Carter. Genetically engineered T cells to target EGFRvIII expressing glioblastoma. J Neurooncol 2009; 94(3):373-82; PMID:19387557; http://dx.doi.org/10.1007/s11060-009-9889-1
33. G.Liu, H.Ying, G.Zeng, C.J.Wheeler, K.L.Black, J.S.Yu. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res 2004; 64(14):4980-6; PMID:15256472; http://dx.doi.org/10.1158/0008-5472.CAN-03-3504
34. U.Sahin, M.Koslowski, O.Türeci, T.Eberle, C.Zwick, B.Romeike, J.R.Moringlane, K.Schwechheimer, W.Feiden, M.Pfreundschuh. Expression of cancer testis genes in human brain tumors. Clin Cancer Res 2000; 6(10):3916-22; PMID:11051238
35. D.L.Scarcella, C.W.Chow, M.F.Gonzales, C.Economou, F.Brasseur, D.M.Ashley. Expression of MAGE and GAGE in high-grade brain tumors:a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res 1999; 5(2):335-41; PMID:10037183
36. K.S.Kahlon, C.Brown, L.J.Cooper, A.Raubitschek, S.J.Forman, M.C.Jensen. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 2004; 64(24):9160-6; PMID:15604287; http://dx.doi.org/10.1158/0008-5472.CAN-04-0454
37. J.G.Zhang, J.Eguchi, C.A.Kruse, G.G.Gomez, H.Fakhrai, S.Schroter, W.Ma, N.Hoa, B.Minev, C.Delgado et al. Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res 2007; 13(2 Pt 1):566-75; PMID:17255279; http://dx.doi.org/10.1158/1078-0432.CCR-06-1576
38. N.Ahmed, V.S.Salsman, Y.Kew, D.Shaffer, S.Powell, Y.J.Zhang, R.G.Grossman, H.E.Heslop, S.Gottschalk. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res 2010; 16(2):474-85; PMID:20068073; http://dx.doi.org/10.1158/1078-0432.CCR-09-1322
39. G.Liu, J.S.Yu, G.Zeng, D.Yin, D.Xie, K.L.Black, H.Ying. AIM-2:a novel tumor antigen is expressed and presented by human glioma cells. J Immunother 2004; 27(3):220-6; PMID:15076139; http://dx.doi.org/10.1097/00002371-200405000-00006
40. R.Ueda, K.Yoshida, T.Kawase, Y.Kawakami, M.Toda. Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients. Int J Cancer 2007; 120(8):1704-11; PMID:17230535; http://dx.doi.org/10.1002/ijc.22472
41. R.Ueda, K.Yoshida, Y.Kawakami, T.Kawase, M.Toda. Expression of a transcriptional factor, SOX6, in human gliomas. Brain Tumor Pathol 2004; 21(1):35-8; PMID:15696967; http://dx.doi.org/10.1007/BF02482175
42. M.Jin, Y.Komohara, S.Shichijo, M.Harada, R.Yamanaka, S.Miyamoto, J.Nikawa, K.Itoh, A.Yamada. Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients. Oncol Rep 2008; 19(5):1277-83; PMID:18425388; http://dx.doi.org/10.3892/or.19.5.1277
43. M.Harada, Y.Ishihara, K.Itoh, R.Yamanaka. Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients. Oncol Rep 2007; 17(3):629-36; PMID:17273744; http://dx.doi.org/10.3892/or.17.3.629
44. M.A.Friese, M.Platten, S.Z.Lutz, U.Naumann, S.Aulwurm, F.Bischof, H.J.Bühring, J.Dichgans, H.G.Rammensee, A.Steinle et al. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res 2003; 63(24):8996-9006; PMID:14695218
45. A.Wu, S.Wiesner, J.Xiao, K.Ericson, W.Chen, W.A.Hall, W.C.Low, J.R.Ohlfest. Expression of MHC I and NK ligands on human CD133+ glioma cells:possible targets of immunotherapy. J Neurooncol 2007; 83(2):121-31; PMID:17077937; http://dx.doi.org/10.1007/s11060-006-9265-3
46. R.Castriconi, A.Daga, A.Dondero, G.Zona, P.L.Poliani, A.Melotti, F.Griffero, D.Marubbi, R.Spaziante, F.Bellora et al. NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol 2009; 182(6):3530-9; PMID:19265131; http://dx.doi.org/10.4049/jimmunol.0802845
47. M.Hatano, J.Eguchi, T.Tatsumi, N.Kuwashima, J.E.Dusak, M.S.Kinch, I.F.Pollack, R.L.Hamilton, W.J.Storkus, H.Okada. EphA2 as a glioma-associated antigen:a novel target for glioma vaccines. Neoplasia 2005; 7(8):717-22; PMID:16207473; http://dx.doi.org/10.1593/neo.05277
48. C.S.Cobbs, L.Harkins, M.Samanta, G.Y.Gillespie, S.Bharara, P.H.King, L.B.Nabors, C.G.Cobbs, W.J.Britt. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 2002; 62(12):3347-50; PMID:12067971
49. M.E.Scheurer, M.L.Bondy, K.D.Aldape, T.Albrecht, R.El-Zein. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol 2008; 116(1):79-86; PMID:18351367; http://dx.doi.org/10.1007/s00401-008-0359-1
50. D.A.Mitchell, W.Xie, R.Schmittling, C.Learn, A.Friedman, R.E.McLendon, J.H.Sampson. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol 2008; 10(1):10-8; PMID:17951512; http://dx.doi.org/10.1215/15228517-2007-035
51. K.G.Lucas, L.Bao, R.Bruggeman, K.Dunham, C.Specht. The detection of CMV pp65 and IE1 in glioblastoma multiforme. J Neurooncol 2011; 103(2):231-8; PMID:20820869; http://dx.doi.org/10.1007/s11060-010-0383-6
52. B.R.Voldborg, L.Damstrup, M.Spang-Thomsen, H.S.Poulsen. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 1997; 8(12):1197-206; PMID:9496384; http://dx.doi.org/10.1023/A:1008209720526
53. C.W.Brennan, R.G.Verhaak, A.McKenna, B.Campos, H.Noushmehr, S.R.Salama, S.Zheng, D.Chakravarty, J.Z.Sanborn, S.H.Berman et al. The somatic genomic landscape of glioblastoma. Cell 2013; 155(2):462-77; PMID:24120142; http://dx.doi.org/10.1016/j.cell.2013.09.034
54. H.S.Huang, M.Nagane, C.K.Klingbeil, H.Lin, R.Nishikawa, X.D.Ji, C.M.Huang, G.N.Gill, H.S.Wiley, W.K.Cavenee. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 1997; 272(5):2927-35; PMID:9006938; http://dx.doi.org/10.1074/jbc.272.5.2927
55. A.B.Heimberger, L.E.Crotty, G.E.Archer, K.R.Hess, C.J.Wikstrand, A.H.Friedman, H.S.Friedman, D.D.Bigner, J.H.Sampson. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 2003; 9(11):4247-54; PMID:14519652
56. C.E.Pelloski, K.V.Ballman, A.F.Furth, L.Zhang, E.Lin, E.P.Sulman, K.Bhat, J.M.McDonald, W.K.Yung, H.Colman et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007; 25(16):2288-94; PMID:17538175; http://dx.doi.org/10.1200/JCO.2006.08.0705
57. N.Shinojima, K.Tada, S.Shiraishi, T.Kamiryo, M.Kochi, H.Nakamura, K.Makino, H.Saya, H.Hirano, J.Kuratsu et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003; 63(20):6962-70; PMID:14583498
58. A.B.Heimberger, R.Hlatky, D.Suki, D.Yang, J.Weinberg, M.Gilbert, R.Sawaya, K.Aldape. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005; 11(4):1462-6; PMID:15746047; http://dx.doi.org/10.1158/1078-0432.CCR-04-1737
59. J.H.Sampson, A.B.Heimberger, G.E.Archer, K.D.Aldape, A.H.Friedman, H.S.Friedman, M.R.Gilbert, J.E.Herndon, 2nd, R.E.McLendon, D.A.Mitchell et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28(31):4722-9; PMID:20921459; http://dx.doi.org/10.1200/JCO.2010.28.6963
60. B.D.Choi, G.E.Archer, D.A.Mitchell, A.B.Heimberger, R.E.McLendon, D.D.Bigner, J.H.Sampson. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 2009; 19(4):713-23; PMID:19744042; http://dx.doi.org/10.1111/j.1750-3639.2009.00318.x
61. J.H.Sampson, K.D.Aldape, G.E.Archer, A.Coan, A.Desjardins, A.H.Friedman, H.S.Friedman, M.R.Gilbert, J.E.Herndon, R.E.McLendon et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 2011; 13(3):324-33; PMID:21149254; http://dx.doi.org/10.1093/neuonc/noq157
62. J.Schuster, R.K.Lai, L.D.Recht, D.A.Reardon, N.A.Paleologos, M.D.Groves, M.M.Mrugala, R.Jensen, J.M.Baehring, A.Sloan et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma:the ACT III study. Neuro Oncol 2015; 17(6):854-61; PMID:25586468; http://dx.doi.org/10.1093/neuonc/nou348
63. Celldex Glioblastoma Candidate Rintega Fails Phase III Trial. 2016 03-07-2016 [cited 201603-16-2016]; Available from:http://www.genengnews.com/gen-news-highlights/celldex-ends-phase-iii-trial-of-glioblastoma-candidate-rintega/81252448/
64. P.K.Srivastava, A.B.DeLeo, L.J.Old. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci U S A 1986; 83(10):3407-11; PMID:3458189; http://dx.doi.org/10.1073/pnas.83.10.3407
65. H.Udono, L.J.Levey, P.K.Srivastava. Cellular requirements for tumor-specific immunity elicited by heat shock proteins:tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc Natl Acad Sci U S A 1994; 91(8):3077-81; PMID:7909157; http://dx.doi.org/10.1073/pnas.91.8.3077
66. R.Y.Chandawarkar, M.S.Wagh, P.K.Srivastava. The dual nature of specific immunological activity of tumor-derived gp96 preparations. J Exp Med 1999; 189(9):1437-42; PMID:10224283; http://dx.doi.org/10.1084/jem.189.9.1437
67. R.J.Binder, P.K.Srivastava. Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc Natl Acad Sci U S A 2004; 101(16):6128-33; PMID:15073331; http://dx.doi.org/10.1073/pnas.0308180101
68. S.Lindquist, E.A.Craig. The heat-shock proteins. Annu Rev Genet 1988; 22:631-77; PMID:2853609; http://dx.doi.org/10.1146/annurev.ge.22.120188.003215
69. O.Bloch, A.T.Parsa. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma:a phase II, single-arm trial. Neuro Oncol 2014; 16(2):274-9; PMID:24335700; http://dx.doi.org/10.1093/neuonc/not203
70. B.Fazeny-Dorner, C.Wenzel, M.Veitl, M.Piribauer, K.Rössler, K.Dieckmann, K.Ungersböck, C.Marosi. Survival and prognostic factors of patients with unresectable glioblastoma multiforme. Anticancer Drugs 2003; 14(4):305-12; PMID:12679735; http://dx.doi.org/10.1097/00001813-200304000-00008
71. L.A.Stewart. Chemotherapy in adult high-grade glioma:a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359(9311):1011-8; PMID:11937180; http://dx.doi.org/10.1016/S0140-6736(02)08091-1
72. Agenus. Agenus Reports Positive Follow-on Phase 2 Results for Brain Cancer Vaccine in Newly Diagnosed Patients. 2013 [cited 2015October29]; Available from:http://www.agenusbio.com/docs/press-releases/2013/positive-phase-2-brain-cancer-vaccine.php
73. S.Constant, D.Sant'Angelo, T.Pasqualini, T.Taylor, D.Levin, R.Flavell, K.Bottomly. Peptide and protein antigens require distinct antigen-presenting cell subsets for the priming of CD4+ T cells. J Immunol 1995; 154(10):4915-23; PMID:7730604
74. D.Levin, S.Constant, T.Pasqualini, R.Flavell, K.Bottomly. Role of dendritic cells in the priming of CD4+ T lymphocytes to peptide antigen in vivo. J Immunol 1993; 151(12):6742-50; PMID:7903097
75. K.Inaba, M.Inaba, N.Romani, H.Aya, M.Deguchi, S.Ikehara, S.Muramatsu, R.M.Steinman. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992; 176(6):1693-702; PMID:1460426; http://dx.doi.org/10.1084/jem.176.6.1693
76. J.D.Campbell, C.Piechaczek, G.Winkels, E.Schwamborn, D.Micheli, S.Hennemann, J.Schmitz. Isolation and generation of clinical-grade dendritic cells using the Clini MACS system. Methods Mol Med 2005; 109:55-70; PMID:15585913; http://dx.doi.org/10.1385/1-59259-862-5:055
77. L.J.Mu, G.Gaudernack, S.Saebøe-Larssen, H.Hammerstad, A.Tierens, G.Kvalheim. A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines. Scand J Immunol 2003; 58(5):578-86; PMID:14629630; http://dx.doi.org/10.1046/j.1365-3083.2003.01333.x
78. R.V.Sorg, Z.Ozcan, T.Brefort, J.Fischer, R.Ackermann, M.Müller, P.Wernet. Clinical-scale generation of dendritic cells in a closed system. J Immunother 2003; 26(4):374-83; PMID:12843800; http://dx.doi.org/10.1097/00002371-200307000-00010
79. S.Tuyaerts, S.M.Noppe, J.Corthals, K.Breckpot, C.Heirman, C.De Greef, I.Van Riet, K.Thielemans. Generation of large numbers of dendritic cells in a closed system using Cell Factories. J Immunol Methods 2002; 264(1–2):135-51; PMID:12191517; http://dx.doi.org/10.1016/S0022-1759(02)00099-6
80. H.Aoki, M.Mizuno, A.Natsume, T.Tsugawa, K.Tsujimura, T.Takahashi, J.Yoshida. Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor. Cancer Immunol Immunother 2001; 50(9):463-8; PMID:11761440; http://dx.doi.org/10.1007/s002620100220
81. L.M.Liau, K.L.Black, R.M.Prins, S.N.Sykes, P.L.DiPatre, T.F.Cloughesy, D.P.Becker, J.M.Bronstein. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 1999; 90(6):1115-24; PMID:10350260; http://dx.doi.org/10.3171/jns.1999.90.6.1115
82. L.M.Liau, R.M.Prins, S.M.Kiertscher, S.K.Odesa, T.J.Kremen, A.J.Giovannone, J.W.Lin, D.J.Chute, P.S.Mischel, T.F.Cloughesy et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005; 11(15):5515-25; PMID:16061868; http://dx.doi.org/10.1158/1078-0432.CCR-05-0464
83. S.Phuphanich, C.J.Wheeler, J.D.Rudnick, M.Mazer, H.Wang, M.A.Nuño, J.E.Richardson, X.Fan, J.Ji, R.M.Chu, J.G.Bender et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 2013; 62(1):125-35; PMID:22847020; http://dx.doi.org/10.1007/s00262-012-1319-0
84. M.D.Siegelin, Y.Siegelin, A.Habel, A.Rami, T.Gaiser. KAAD-cyclopamine augmented TRAIL-mediated apoptosis in malignant glioma cells by modulating the intrinsic and extrinsic apoptotic pathway. Neurobiol Dis 2009; 34(2):259-66; PMID:19385057; http://dx.doi.org/10.1016/j.nbd.2009.01.012
85. C.E.Fadul, J.L.Fisher, T.H.Hampton, E.C.Lallana, Z.Li, J.Gui, Z.M.Szczepiorkowski, T.D.Tosteson, C.H.Rhodes, H.A.Wishart et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother 2011; 34(4):382-9; PMID:21499132; http://dx.doi.org/10.1097/CJI.0b013e318215e300
86. I.F.Pollack, R.I.Jakacki, L.H.Butterfield, R.L.Hamilton, A.Panigrahy, D.M.Potter, A.K.Connelly, S.A.Dibridge, T.L.Whiteside, H.Okada. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol 2014; 32(19):2050-8; PMID:24888813; http://dx.doi.org/10.1200/JCO.2013.54.0526
87. J.L.Lasky, 3rd, E.H.Panosyan, A.Plant, T.Davidson, W.H.Yong, R.M.Prins, L.M.Liau, T.B.Moore. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res 2013; 33(5):2047-56; PMID:23645755
88. H.Ardon, S.De Vleeschouwer, F.Van Calenbergh, L.Claes, C.M.Kramm, S.Rutkowski, J.E.Wolff, S.W.Van Gool. Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer 2010; 54(4):519-25; PMID:19852061; http://dx.doi.org/10.1002/pbc.22319
89. F.Azimi, R.A.Scolyer, P.Rumcheva, M.Moncrieff, R.Murali, S.W.McCarthy, R.P.Saw, J.F.Thompson. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 2012; 30(21):2678-83; PMID:22711850; http://dx.doi.org/10.1200/JCO.2011.37.8539
90. B.Kreike, M.van Kouwenhove, H.Horlings, B.Weigelt, H.Peterse, H.Bartelink, M.J.van de Vijver. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007; 9(5):R65; PMID:17910759; http://dx.doi.org/10.1186/bcr1771
91. S.M.Mahmoud, E.C.Paish, D.G.Powe, R.D.Macmillan, M.J.Grainge, A.H.Lee, I.O.Ellis, A.R.Green. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29(15):1949-55; PMID:21483002; http://dx.doi.org/10.1200/JCO.2010.30.5037
92. S.Rusakiewicz, M.Semeraro, M.Sarabi, M.Desbois, C.Locher, R.Mendez, N.Vimond, A.Concha, F.Garrido, N.Isambert et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res 2013; 73(12):3499-510; PMID:23592754; http://dx.doi.org/10.1158/0008-5472.CAN-13-0371
93. Herold-Mende C, Mossermann J, Jungk C, Ahmadi R, Capper D, von Deimling A, Unterberg A, Beckhove P. Spontaneous immune responses in gbm patients after complete tumor resection are associated with an improved survival. Neuro-Oncology 2014; 16(suppl 3):iii42; http://dx.doi.org/10.1093/neuonc/nou209.1
94. J.Kmiecik, A.Poli, N.H.Brons, A.Waha, G.E.Eide, P.Ø.Enger, J.Zimmer, M.Chekenya. Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol 2013; 264(1–2):71-83; PMID:24045166; http://dx.doi.org/10.1016/j.jneuroim.2013.08.013
95. T.Ohkuri, A.Ghosh, A.Kosaka, J.Zhu, M.Ikeura, M.David, S.C.Watkins, S.N.Sarkar, H.Okada. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res 2014; 2(12):1199-208; PMID:25300859; http://dx.doi.org/10.1158/2326-6066.CIR-14-0099
96. S.R.Woo, L.Corrales, T.F.Gajewski. The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol 2015; 36(4):250-6; PMID:25758021; http://dx.doi.org/10.1016/j.it.2015.02.003
97. H.Miao, B.D.Choi, C.M.Suryadevara, L.Sanchez-Perez, S.Yang, G.De Leon, E.J.Sayour, R.McLendon, J.E.Herndon, P.Healy et al. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PLoS One 2014; 9(4):e94281; PMID:24722266; http://dx.doi.org/10.1371/journal.pone.0094281
98. Z.Eshhar, T.Waks, G.Gross, D.G.Schindler. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993; 90(2):720-4; PMID:8421711; http://dx.doi.org/10.1073/pnas.90.2.720
99. M.Sadelain, I.Riviere, R.Brentjens. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003; 3(1):35-45; PMID:12509765; http://dx.doi.org/10.1038/nrc971
100. M.Pule, H.Finney, A.Lawson. Artificial T-cell receptors. Cytotherapy 2003; 5(3):211-26; PMID:12850789; http://dx.doi.org/10.1080/14653240310001488
101. A.K.Wege, W.Ernst, J.Eckl, B.Frankenberger, A.Vollmann-Zwerenz, D.N.Männel, O.Ortmann, A.Kroemer, G.Brockhoff. Humanized tumor mice–a new model to study and manipulate the immune response in advanced cancer therapy. Int J Cancer 2011; 129(9):2194-206; PMID:21544806; http://dx.doi.org/10.1002/ijc.26159
102. M.A.Brehm, M.V.Wiles, D.L.Greiner, L.D.Shultz. Generation of improved humanized mouse models for human infectious diseases. J Immunol Methods 2014; 410:3-17; PMID:24607601; http://dx.doi.org/10.1016/j.jim.2014.02.011
103. K.E.Aryee, L.D.Shultz, M.A.Brehm. Immunodeficient mouse model for human hematopoietic stem cell engraftment and immune system development. Methods Mol Biol 2014; 1185:267-78; PMID:25062635; http://dx.doi.org/10.1007/978-1-4939-1133-2_18
104. E.Billerbeck, W.T.Barry, K.Mu, M.Dorner, C.M.Rice, A.Ploss. Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2Rgamma(null) humanized mice. Blood 2011; 117(11):3076-86; PMID:21252091; http://dx.doi.org/10.1182/blood-2010-08-301507
105. S.R.Evans. Clinical trial structures. J Exp Stroke Transl Med 2010; 3(1):8-18; PMID:21423788; http://dx.doi.org/10.6030/1939-067X-3.1.8
106. A.Schuessler, C.Smith, L.Beagley, G.M.Boyle, S.Rehan, K.Matthews, L.Jones, T.Crough, V.Dasari, K.Klein et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res 2014; 74(13):3466-76; PMID:24795429; http://dx.doi.org/10.1158/0008-5472.CAN-14-0296
107. D.A.Mitchell, K.A.Batich, M.D.Gunn, M.N.Huang, L.Sanchez-Perez, S.K.Nair, K.L.Congdon, E.A.Reap, G.E.Archer, A.Desjardins et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 2015; 519(7543):366-9; PMID:25762141; http://dx.doi.org/10.1038/nature14320
108. T.Schumacher, L.Bunse, W.Wick, M.Platten. Mutant IDH1:An immunotherapeutic target in tumors. Oncoimmunology 2014; 3(12):e974392; PMID:25964867; http://dx.doi.org/10.4161/2162402X.2014.974392
109. T.Schumacher, L.Bunse, S.Pusch, F.Sahm, B.Wiestler, J.Quandt, O.Menn, M.Osswald, I.Oezen, M.Ott et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014; 512(7514):324-7; PMID:25043048; http://dx.doi.org/10.1038/nature13387
110. D.W.Parsons, S.Jones, X.Zhang, J.C.Lin, R.J.Leary, P.Angenendt, P.Mankoo, H.Carter, I.M.Siu, G.L.Gallia et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321(5897):1807-12; PMID:18772396; http://dx.doi.org/10.1126/science.1164382
111. J.W.Dennis, S.Laferté, C.Waghorne, M.L.Breitman, R.S.Kerbel. Beta 1–6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science 1987; 236(4801):582-5; PMID:2953071; http://dx.doi.org/10.1126/science.2953071
112. S.Sell. Cancer-associated carbohydrates identified by monoclonal antibodies. Hum Pathol 1990; 21(10):1003-19; PMID:2210723; http://dx.doi.org/10.1016/0046-8177(90)90250-9
113. A.Kobata, J.Amano. Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours. Immunol Cell Biol 2005; 83(4):429-39; PMID:16033539; http://dx.doi.org/10.1111/j.1440-1711.2005.01351.x
114. Y.W.Lou, P.Y.Wang, S.C.Yeh, P.K.Chuang, S.T.Li, C.Y.Wu, K.H.Khoo, M.Hsiao, T.L.Hsu, C.H.Wong. Stage-specific embryonic antigen-4 as a potential therapeutic target in glioblastoma multiforme and other cancers. Proc Natl Acad Sci U S A 2014; 111(7):2482-7; PMID:24550271; http://dx.doi.org/10.1073/pnas.1400283111
115. T.Freire, S.Bay, S.von Mensdorff-Pouilly, E.Osinaga. Molecular basis of incomplete O-glycan synthesis in MCF-7 breast cancer cells:putative role of MUC6 in Tn antigen expression. Cancer Res 2005; 65(17):7880-7; PMID:16140958; http://dx.doi.org/10.1158/0008-5472.CAN-04-3746
116. J.Kanitakis, I.al-Rifai, M.Faure, A.Claudy. Differential expression of the cancer associated antigens T (Thomsen-Friedenreich) and Tn to the skin in primary and metastatic carcinomas. J Clin Pathol 1998; 51(8):588-92; PMID:9828816; http://dx.doi.org/10.1136/jcp.51.8.588
117. G.Ohshio, T.Imamura, M.Imamura, H.Yamabe, H.Sakahara, H.Nakada, I.Yamashina. Distribution of Tn antigen recognized by an anti-Tn monoclonal antibody (MLS128) in normal and malignant tissues of the digestive tract. J Cancer Res Clin Oncol 1995; 121(4):247-52; PMID:7751324; http://dx.doi.org/10.1007/BF01366970
118. C.L.Brooks, A.Schietinger, S.N.Borisova, P.Kufer, M.Okon, T.Hirama, C.R.Mackenzie, L.X.Wang, H.Schreiber, S.V.Evans. Antibody recognition of a unique tumor-specific glycopeptide antigen. Proc Natl Acad Sci U S A 2010; 107(22):10056-61; PMID:20479270; http://dx.doi.org/10.1073/pnas.0915176107
119. S.Inman. Rintega (Rindopepimut) Misses Survival Endpoint in Phase 3 Glioblastoma Trial. Brain Cancer Cure 2016 03-10-2016 [cited 201604-19-2016]; Available from:http://www.curetoday.com/articles/rintega-misses-survival-endpoint-in-phase-3-glioblastoma-trial
120. D chaperone protein. Clin Cancer Res 2013; 19(1):205-14; PMID:22872572; http://dx.doi.org/10.1158/1078-0432.CCR-11-3358
121. P.C.Gedeon, B.D.Choi, J.H.Sampson, D.D.Bigner. Rindopepimut:anti-EGFRvIII peptide vaccine, oncolytic. Drugs Future 2013; 38(3):147-155; PMID:25663738; http://dx.doi.org/10.1358/dof.2013.038.03.1933992
122. K.A.Ahmed, T.Sawa, H.Ihara, S.Kasamatsu, J.Yoshitake, M.M.Rahaman, T.Okamoto, S.Fujii, T.Akaike. Regulation by mitochondrial superoxide and NADPH oxidase of cellular formation of nitrated cyclic GMP:potential implications for ROS signalling. Biochem J 2012; 441(2):719-30; PMID:21967515; http://dx.doi.org/10.1042/BJ20111130